U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13NO2.ClH
Molecular Weight 203.666
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLEPHRINE HYDROCHLORIDE

SMILES

Cl.CNC[C@H](O)C1=CC(O)=CC=C1

InChI

InChIKey=OCYSGIYOVXAGKQ-FVGYRXGTSA-N
InChI=1S/C9H13NO2.ClH/c1-10-6-9(12)7-3-2-4-8(11)5-7;/h2-5,9-12H,6H2,1H3;1H/t9-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Curator's Comment: Phenylephrine does not cross the blood–brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
55.0 nM [EC50]
5.9 nM [EC50]
154.88 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VAZCULEP

Approved Use

VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Launch Date

1953
Diagnostic
Phenylephrine Hydrochloride Ophthalmic Solution

Approved Use

Indicated to dilate the pupil

Launch Date

1938
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2959 pg/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4492 pg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1354 pg/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2346 pg × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3900 pg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
955.8 pg × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.93 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.64 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.89 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (acute)
Sources:
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Disc. AE: Chest pain, Jaw pain...
Other AEs: Nervous system disorders, Headache...
AEs leading to
discontinuation/dose reduction:
Chest pain (1 patient)
Jaw pain (1 patient)
Other AEs:
Nervous system disorders (3.6%)
Headache (2.7%)
Gastrointestinal disorders (8%)
Dry mouth (2.7%)
Nausea (3.6%)
Sources:
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Other AEs: Eye pain, Blurred vision...
Other AEs:
Eye pain
Blurred vision
Photophobia
Allergic conjunctivitis
Sources:
250 ug single, intravenous
Recommended
Dose: 250 ug
Route: intravenous
Route: single
Dose: 250 ug
Sources:
unhealthy, adult
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis acute
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Jaw pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Dry mouth 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Headache 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nausea 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nervous system disorders 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Gastrointestinal disorders 8%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Allergic conjunctivitis
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Blurred vision
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Eye pain
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Photophobia
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release.
2000 Dec 1
The effect of phenylephrine on pain and flare intensity in eyes with uveitis.
2000 Oct
Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis.
2000 Sep
Contribution of ryanodine receptor subtype 3 to ca2+ responses in Ca2+-overloaded cultured rat portal vein myocytes.
2001 Apr 6
Influence of a multideficient diet from northeastern Brazil on resting blood pressure and baroreflex sensitivity in conscious, freely moving rats.
2001 Feb
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1.
2001 Feb
Reflex cardiovascular responses originating in exercising muscles of mice.
2001 Feb
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility.
2001 Feb
Nitric oxide-mediated arteriolar dilation after endothelial deformation.
2001 Feb
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control.
2001 Feb
Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1.
2001 Feb
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.
2001 Feb
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin.
2001 Feb 1
Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin.
2001 Feb 13
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Ras regulates NFAT3 activity in cardiac myocytes.
2001 Feb 2
Depletion of phosphatidylinositol 4,5-bisphosphate by activation of phospholipase C-coupled receptors causes slow inhibition but not desensitization of G protein-gated inward rectifier K+ current in atrial myocytes.
2001 Feb 23
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles.
2001 Feb 7
Methylene blue as a successful treatment alternative for pharmacologically induced priapism.
2001 Jan
Detection and characterization of cholinergic oscillatory control in the forehead microvasculature in response to systemic alpha-agonist infusion in healthy volunteers.
2001 Jan
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors.
2001 Jan
Activity of cardiorespiratory networks revealed by transsynaptic virus expressing GFP.
2001 Jan
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.
2001 Jan
Increased dilator response to heptanol and octanol in aorta from DOCA-salt-hypertensive rats.
2001 Jan
Exercise attenuates alpha-adrenergic-receptor responsiveness in skeletal muscle vasculature.
2001 Jan
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.
2001 Jan
Should the angiotensin II antagonists be discontinued before surgery?
2001 Jan
Effects of acute and chronic hypertension on the labyrinthine barriers in rat.
2001 Jan
CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR.
2001 Jan
Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats.
2001 Jan
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.
2001 Jan
Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release.
2001 Jan
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.
2001 Jan
A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats.
2001 Jan
alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle.
2001 Jan
Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction.
2001 Jan
Hepatic neovascularization after partial portal vein ligation: novel mechanism of chronic regulation of blood flow.
2001 Jan
Assessment of baroreflex sensitivity in patients with preserved and impaired left ventricular function by means of the Valsalva manoeuvre and the phenylephrine test.
2001 Jan
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.
2001 Jan 12
Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci.
2001 Jan 15
Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium.
2001 Jan 19
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.
2001 Jan 19
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.
2001 Jan-Feb
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001 Mar
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.
2001 Mar
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.
2001 Mar
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries.
2001 Mar
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.
2001 Mar
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.
2001 Mar
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Also used as Ophthalmic Solution or oral tablets http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.
Route of Administration: Intravenous
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Name Type Language
PHENYLEPHRINE HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
PROMETHAZINE VC COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Common Name English
PHENYLEPHRINE HCL
Common Name English
PHENYLEPHRINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
BIOMYDRIN
Brand Name English
BIORPHEN
Brand Name English
NSC-757273
Code English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF PREFRIN-A
Common Name English
ADVIL CONGESTION RELIEF COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Common Name English
PHENYLEPHRINE HYDROCHLORIDE [MART.]
Common Name English
PHENYLEPHRINE HYDROCHLORIDE [USP-RS]
Common Name English
PHENYLEPHRINE HYDROCHLORIDE [MI]
Common Name English
PHENYLEPHRINE HYDROCHLORIDE [VANDF]
Common Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF PHENERGAN VC
Common Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF ADVIL CONGESTION RELIEF
Common Name English
MYDCOMBI COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Brand Name English
PHERAZINE VC COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Common Name English
OMIDRIA COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Brand Name English
MYDFRIN
Brand Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF PROMETHAZINE VC
Common Name English
NEO-SYNEPHRINE
Brand Name English
PREFRIN-A COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Common Name English
AFRIN 4 HOUR NASAL SPRAY
Brand Name English
PHENERGAN VC COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Common Name English
(-)-M-HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZYL ALCOHOL HYDROCHLORIDE
Systematic Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF CYCLOMYDRIL
Common Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF OMIDRIA
Brand Name English
PHENYLEPHRINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
VAZCULEP
Brand Name English
NOSTRIL
Brand Name English
PHENYLEPHRINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF MYDCOMBI
Brand Name English
PHENYLEPHRINE HYDROCHLORIDE [JAN]
Common Name English
PHENYLEPHRINE HYDROCHLORIDE COMPONENT OF PHERAZINE VC
Common Name English
Phenylephrine hydrochloride [WHO-DD]
Common Name English
BENZENEMETHANOL, 3-HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)-, HYDROCHLORIDE (R)-
Systematic Name English
CYCLOMYDRIL COMPONENT PHENYLEPHRINE HYDROCHLORIDE
Common Name English
Classification Tree Code System Code
CFR 21 CFR 349.18
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
CFR 21 CFR 346.12
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
NCI_THESAURUS C29709
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
EU-Orphan Drug EU/3/01/069
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
CFR 21 CFR 341.20
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
Code System Code Type Description
CHEBI
8094
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL1215
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
SMS_ID
100000090176
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
MERCK INDEX
m8668
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C29363
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
EVMPD
SUB03777MIG
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
PUBCHEM
441279
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
CAS
61-76-7
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
RXCUI
8164
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY RxNorm
FDA UNII
04JA59TNSJ
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID3021142
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
NSC
757273
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
DAILYMED
04JA59TNSJ
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
DRUG BANK
DBSALT000858
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-517-3
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY
RS_ITEM_NUM
1533002
Created by admin on Fri Dec 15 15:03:26 GMT 2023 , Edited by admin on Fri Dec 15 15:03:26 GMT 2023
PRIMARY